ACRV
HEALTHCAREAcrivon Therapeutics, Inc. Common Stock
AI Insight
What's Moving ACRV Today?
No stock-specific AI insight has been generated for ACRV yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.15$3.56
$1.62
Fundamentals
Market Cap$70M
P/E Ratio—
EPS$-2.00
Dividend Yield—
Dividend / Share—
ROE-60.4%
Profit Margin—
Debt / Equity—
Trading
Volume293K
Avg Volume (10D)—
Shares Outstanding42.8M
ACRV News
22 articles- Acrivon Therapeutics (ACRV) shareholders approve larger equity plan and elect directorsStock Titan·Jun 18, 2026
- Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation SummitYahoo Finance·May 21, 2026
- [Form 4] Acrivon Therapeutics, Inc. Insider Trading ActivityStock Titan·May 19, 2026
- Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 15, 2026
- Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical CatalystsYahoo Finance·May 13, 2026
- Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development OpportunitiesGlobeNewswire Inc.·Apr 17, 2026
- Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Mar 19, 2026
- Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint InhibitorsYahoo Finance·Mar 17, 2026
- Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's WhyYahoo Finance·Mar 3, 2026
- Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial CancerMarketbeat·Feb 27, 2026
- Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 24, 2026
- Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) CongressYahoo Finance·Feb 23, 2026
- Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified LaboratoryYahoo Finance·Feb 18, 2026
- Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International CongressYahoo Finance·Jan 23, 2026
- Penny Stocks To Watch In January 2026Yahoo Finance·Jan 19, 2026
- Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More SharesYahoo Finance·Jan 18, 2026
- Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11Yahoo Finance·Jan 8, 2026
- Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?Yahoo Finance·Jan 7, 2026
- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via WebcastYahoo Finance·Jan 6, 2026
- UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via WebcastYahoo Finance·Dec 17, 2025
- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline UpdatesYahoo Finance·Dec 17, 2025
- 3 Promising Penny Stocks With Market Caps Over $70MYahoo Finance·Dec 11, 2025
All 22 articles loaded
Price Data
Open$1.63
Previous Close$1.63
Day High$1.70
Day Low$1.62
52 Week High$3.56
52 Week Low$1.15
52-Week Range
$1.15$3.56
$1.62
Fundamentals
Market Cap$70M
P/E Ratio—
EPS$-2.00
Dividend Yield—
Dividend / Share—
ROE-60.4%
Profit Margin—
Debt / Equity—
Trading
Volume293K
Avg Volume (10D)—
Shares Outstanding42.8M
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of precision cancer medicines. The company is headquartered in Watertown, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—